CSRXP: INSULIN ACT MAY PROVIDE SHORT TERM RELIEF FOR SOME PATIENTS BUT WON’T ADDRESS ROOT CAUSE OF OUT-OF-CONTROL DRUG PRICES
Congress Must Advance Bipartisan, Market-Based Solutions to Hold Big Pharma… Read More
Congress Must Advance Bipartisan, Market-Based Solutions to Hold Big Pharma… Read More
Joint Effort Aims to Curb Anti-Competitive Tactics Used by Brand Name Drug… Read More
Brand Name Drug Companies Begin Second Round of Biannual Price Hikes While… Read More
PhRMA Ads Falsely Claim the Industry’s Egregious Pricing Practices Don’t… Read More
Committee Report Shows How Brand Name Drug Company Further Juiced Profits on… Read More
Congress Should Swiftly Advance Solutions to Deliver Relief for Millions of… Read More
Lawmakers Can Highlight Tactics Designed to Block More Affordable Alternatives… Read More
Big Pharma Trots Out Tired, Dishonest Arguments Designed to Evade… Read More
Federal Trade Commission Workshop Highlights How Brand Name Drug Companies… Read More
FTC Workshop Can Highlight How Brand Name Drug Companies Employ… Read More
Nearly Half of All New Brand Name Drugs Cost More Than $150,000 Per Year In… Read More
Scoring Shows Solutions to Crack Down on Branded Drug Companies’… Read More